Document is current

Article History

Accepted: 20 March 2025

First Online: 23 April 2025

Declarations

:

: This study, and open access for the publication of this article, were funded by F. Hoffmann-La Roche Ltd. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Sean R Mills and Laura Vergoz, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd.

: Substantial contributions to the conception or design of the work: all authors. Data analysis: N.J., S.V., A.H., and J.T. Interpretation of data for the work: all authors. Drafting the work or reviewing it critically for important intellectual content: all authors. Final approval of the version to be published: all authors.

: Nick Jovanoski, Sarah Vaselenak, Andrew Hogan, Jasmine Turki: employment at Roche; Nick Jovanoski, Andrew Hogan: holds stocks at Roche; Quincy Chu: honoraria from consultation with AbbVie, Amgen, AnHeart, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genprex, GSK, Janssen, Merck, Novartis, Ocellaris, Pfizer, Roche, and Takeda, research fundings from AstraZeneca and Roche, and former Data and Safety Monitoring Board member for Merck KgaA.

: Not applicable.

: Not applicable.

: Not applicable.

: For eligible studies qualified researchers may request access to individual patient level clinical data through a data request platform. At the time of writing this request platform is Vivli. . For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: . Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked owing to a potential increase in risk of patient re-identification.

: Not applicable.